These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3895561)

  • 21. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
    Cassels R; Fears R; Smith RA
    Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration.
    Bookstein JJ; Saldinger E
    Invest Radiol; 1985 Oct; 20(7):731-5. PubMed ID: 2933363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of efficacy of thrombolysin, streptokinase, and urokinase in a femoral vein clot model in rats.
    Cooley BC; Jones MM; Dellon AL
    Microsurgery; 1983; 4(1):1-4. PubMed ID: 6226846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anistreplase. Pharmacology and biological data].
    Samama M
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():15-20. PubMed ID: 2108641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
    Ogloblina OG; Saburova OS; Semenova OA; Belova LA
    Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
    Nielsen VG
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
    Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
    Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The systemic fibrinolytic effect of BRL 26921 during the treatment of acute peripheral arterial occlusions.
    Earnshaw JJ; Westby JC; Makin GS; Hopkinson BR
    Thromb Haemost; 1986 Apr; 55(2):259-62. PubMed ID: 3520938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Streptokinase and anisoylated streptokinase plasminogen complex. Their action on haemostasis in human volunteers.
    Staniforth DH; Smith RA; Hibbs M
    Eur J Clin Pharmacol; 1983; 24(6):751-6. PubMed ID: 6350023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for the progressive uptake of anisoylated plasminogen streptokinase activator complex by clots in human plasma in vitro.
    Fears R; Ferres H; Standring R
    Drugs; 1987; 33 Suppl 3():51-6. PubMed ID: 2960513
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effectiveness of acylated thrombolytic agents in lysis of blood plasma clots from humans and various animals].
    Aĭsina RB; Bashkov GV; Eremeev NL; Popova GIu; Kazanskaia NF
    Ukr Biokhim Zh (1978); 1991; 63(2):31-9. PubMed ID: 1882461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.